OR WAIT null SECS
June 09, 2021
Past lessons, strong resolve, and complex coordination propel J&J’s vaccine efforts.
Thrust into a commercial-stage company in just months, Moderna moves full steam ahead.
College roommates, industry partnerships help bring Pfizer vaccine to fruition.
June 08, 2021
The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.
May 27, 2021
The field of longevity therapeutics — with the goal “of not just adding years to life but adding life to years” — is already disrupting the medical industry, writes Marco Quarta.
May 14, 2021
Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.
April 27, 2021
Pascal Descargues, Ph.D., founder of Genoskin, talks about how the company is responding to the US government’s push to help pharma and biotech leaders speed clinical drug development and testing.
Insights and examples of how collaborative efforts can lead to the development of innovative therapies that target unmet patient needs.
March 22, 2021
The shift to clinical-grade support offers great opportunity.
March 16, 2021
Dr. Matthias Schmidt talks about his new role leading the US subsidiary of Japan’s JCR Pharmaceuticals after a “far-from-easy” merger last year.
